Dr. Park on ​the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL | OncLive

Dr. Park on ​the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL

August 10, 2020

Jae Park, MD, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia (ALL).

Patients with low lymphocyte counts after chemotherapy or allogeneic stem cell transplantation ​could benefit from off-the-shelf CAR T-cell products as collecting T cells can be challenging, says Park.

Moreover, patients may experience disease progression during the 3 to 4-week period of T-cell generation that may be mitigated by an off-the-shelf option, concludes Park.


x